Letter to the Editor: Saroglitazar for Treatment of NAFLD and NASH
- PMID: 34365663
- DOI: 10.1002/hep.32094
Letter to the Editor: Saroglitazar for Treatment of NAFLD and NASH
Comment on
-
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.Hepatology. 2021 Oct;74(4):1809-1824. doi: 10.1002/hep.31843. Epub 2021 Jul 19. Hepatology. 2021. PMID: 33811367 Clinical Trial.
References
-
- Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, et al. Saroglitazar, a PPAR-α/γ agonist, for treatment of nonalcoholic fatty liver disease: a randomized controlled double-blind phase 2 trial. Hepatology 2021 Apr 2. https://doi.org/10.1002/hep.31843. [Epub ahead of print]
-
- Sharma M, Premkumar M, Kulkarni AV, Kumar P, Reddy DN, Rao NP, et al. Drugs for non-alcoholic steatohepatitis (NASH): quest for the holy grail. J Clin Transl Hepatol 2021;9:40-50.
-
- Maximos M, Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Biernacki D, et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology 2015;61:153-160.
-
- Verma S, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int 2013;33:1398-1405.
-
- Ma X, Liu S, Zhang J, Dong M, Wang Y, Wang M, et al. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis. BMC Gastroenterol 2020;20:10.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources